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 INTRODUCTION
The cloning of receptors for the peptide growth factors activin
(Mathews and Vale, 1991; Attisano et al., 1992) and TGF-b
(Lin et al., 1992, Ebner et al., 1993) has provided information
about their overall structure and the molecular mechanism of
signal transduction. The activin receptor types II and IIB and
the TGF-b receptor types I and II, together with the C. elegans
orphan receptor Daf-1 (Georgi et al., 1990) and several
recently cloned rat orphan receptors (He et al., 1993), consti-
tute a new subfamily of transmembrane protein kinase
receptors. Based upon its primary structure, the kinase domain
has a predicted specificity for serine and threonine residues.
However, the mouse activin receptor type IIB has been shown
to contain serine, threonine and tyrosine kinase activity
(Nakamura et al., 1992).
The terms type II and type I refer to the nomenclature that
is used for the different TGF-b receptors that have been
described (Cheifetz et al., 1987). Crosslinking of radiolabelled
TGF- b to cellular proteins allowed the identification of at least
three different TGF-b binding proteins at the cell surface,
named TGF-b receptor types I, II and III according to their
relative molecular masses of 55, 80 and 280· 103, respectively.
The type III receptor is a betaglycan without a signalling motif
(Wang et al., 1991), and is thought to play a role in the pre-
sentation and binding of TGF-b to the other receptor types
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The activin and TGF-b type II receptors are members of a
separate subfamily of transmembrane receptors with
intrinsic protein kinase activity, which also includes the
recently cloned TGF-b type I receptor. We have isolated
and characterized a cDNA clone (C14) encoding a new
member of this subfamily. The domain structure of the
C14-encoded protein corresponds with the structure of the
other known transmembrane serine/threonine kinase
receptors. It also contains the two inserts in the kinase
domain that are characteristic for this subfamily. Using in
situ hybridization, C14 mRNA was detected in the mes-
enchymal cells located adjacent to the müllerian ducts of
males and females at day 15 (E15) of embryonic develop-
ment. Marked C14 mRNA expression was also detected in
the female gonads. In female E16 embryos, the C14 mRNA
expression pattern remained similar to that in E15
embryos. However, in male E16 embryos C14 mRNA was
detected in a circular area that includes the degenerating
müllerian duct. The expression of C14 mRNA was also
studied using RNase protection assays. At E15 and E16,
C14 mRNA is expressed in the female as well as in the male
urogenital ridge. However, at E19, a high C14 mRNA level
in the female urogenital ridge contrasts with a lack of C14
mRNA in the male urogenital ridge. This correlates with
the almost complete degeneration of the müllerian ducts in
male embryos at E19. C14 mRNA expression was also
detected in embryonic testes at E15, E16 and E19 using
RNase protection assays, but at much lower levels than
those found in the developing ovaries. In eleven other
tissues no C14 mRNA was observed.
The results point to anti-müllerian hormone (AMH)
being the most likely candidate ligand for C14. The
embryonic C14 mRNA expression pattern in the urogeni-
tal ridge correlates with the expected site of AMH action,
and C14 mRNA expression in the fetal ovary is in
agreement with known effects of AMH on gonadal differ-
entiation. 
Postnatal C14 mRNA expression in rats was found to be
confined mainly to the gonads. In the testis, C14 mRNA
expression occurs in Sertoli cells. This testicular expression
markedly increases during the first 3 weeks after birth,
concurrent with the onset of spermatogenesis.
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(López-Casillas et al., 1993). The TGF-b type I receptor cannot
bind TGF-b in the absence of the type II receptor (Wrana et
al., 1992, Ebner et al., 1993), and association with the type I
receptor is essential for the TGF-b type II receptor to signal
growth inhibition (Wrana et al., 1992). It is thought that this
obligatory association between type I and type II receptors is
a functional characteristic for all members of the
serine/threonine kinase receptor family (Wrana et al., 1992).
However, there are also indications that for some cellular
responses to TGF-b the presence of only the type I or type II
TGF- b receptor might be sufficient (Chen et al., 1993).
In this report, we describe the cloning and characterization
of a rat cDNA, termed C14, which encodes a new member of
the serine/threonine kinase receptor family. Based upon the
cell-/tissue-specific C14 mRNA expression pattern, described
herein, it will be discussed that the most likely candidate ligand
of C14 is anti-müllerian hormone (AMH) (also called
müllerian inhibiting substance; MIS). 
AMH is a member of the activin and TGF- b family of
peptide growth factors (Cate et al., 1986). These signalling
molecules share numerous structural similarities. They are syn-
thesized as large precursor molecules that form homo- or
hetero-dimers. Each chain of the dimer is cleaved at approxi-
mately 110 amino acids from the C terminus, which generates
the mature subunit and an N-terminal proregion. Sequence
identity between members of this growth factor family is found
mainly in the C-terminal mature subunits (25-80%; for review
see: Massagué et al., 1990). 
The known action of AMH in sex differentiation is very
specific, when compared with the variety of functions that are
performed by most other growth factors of the same family.
For example, activin may regulate the secretion of follicle-
stimulating hormone (FSH) by the pituitary gland (Vale et al.,
1988), but also plays different roles in erythroid cell differen-
tiation (Yu et al., 1987), neural cell survival (Schubert et al.,
1990), and during embryogenesis (Thomsen et al., 1990;
Hemmati-Brivanlou and Melton, 1992). 
AMH is the earliest protein product known to be secreted by
Sertoli cells in the fetal testis (Tran and Josso, 1982). Around
day 15 of embryonic development in the male rat, AMH
induces the regression of the müllerian ducts, which form the
anlagen of the uterus, oviducts, and upper vagina. The Leydig
cells in the developing testis produce testosterone, which stim-
ulates the differentiation of the wolffian ducts into epi-
didymides, vasa deferens and seminal vesicles. The window of
sensitivity of the müllerian duct to AMH in the rat has been
shown to be between E14.5-E15.5. After E16, exposure to
AMH does not result in müllerian duct regression (Josso et al.,
1977; Tsuji et al., 1992). In female embryos, the lack of
androgens leads to wolffian duct regression, and the müllerian
duct persists because the ovarian cells do not produce AMH.
All these events form part of the earliest steps in sex differen-
tiation following gonadal sex determination. In addition to its
effect upon the müllerian duct, AMH may have a role to play
in the development of ovaries and testes (Münsterberg and
Lovell-Badge, 1991; Hirobe et al., 1992). The cellular
mechanism by which AMH induces müllerian duct regression
is poorly understood. Recent results show that AMH elicits its
effect upon the müllerian duct epithelium most likely via the
surrounding mesenchymal cells (Tsuji et al., 1992).
The expression of C14 mRNA during embryonic sex differ-
entiation, described in the present report, is in accordance with
the hypothesis that C14 encodes a type I/II receptor for AMH.
MATERIALS AND METHODS
Tissue and RNA preparations
Sertoli cells and peritubular myoid cells were isolated from 21-day-
old rats and cultured as described previously (Themmen et al., 1991;
Blok et al., 1992). Round spermatids were isolated from 35-day-old
rats as described by Grootegoed et al. (1986). Total tissues, isolated
cell fractions, or cultured cells were snap frozen in liquid nitrogen and
stored at - 70˚C until used for RNA isolation. Total RNA was isolated
using the LiCl/urea method (Aufray and Rougeon, 1980).
Isolation of C14 from a rat Sertoli cell cDNA library
Sertoli cells were cultured for 6 hours without (- T) or with 0.6 µM
testosterone (+T), in the presence of 50 µg/ml cycloheximide. These
cells were used to prepare - T and +T cDNA libraries in Lambda
ZAPII (Stratagene, Westburg, Leusden, The Netherlands), using
standard molecular biology techniques (Sambrook et al., 1989). All
radiolabelled agents were from Amersham (‘s Hertogenbosch, The
Netherlands). A +T-enriched subtracted probe was prepared (Sive and
St John, 1988), using in vitro synthesized cRNA from the - T cDNA
library as driver RNA. RNA was synthesized using an in vitro RNA
transcription kit (Stratagene) according to the instructions of the man-
ufacturer. Clones from the +T cDNA library that showed a stronger
hybridization signal with the subtracted probe than with a - T cDNA
probe were isolated, and possible induction by androgens was tested
on northern blots containing +T and - T total RNA. Northern blotting
and random-primed labelling of the C14 cDNA with [32P]dATP was
performed according to Sambrook et al. (1989). C14 mRNA
expression initially seemed to be androgen responsive, but this was
not confirmed in later experiments (Fig. 1).
Sequencing
The complete 1.9 kb C14 cDNA clone was sequenced on both strands
using the dideoxy chain termination method (Sanger et al., 1977). The
sequence was analyzed using the sequence analysis program Micro-
genie (Beckmann, Mijdrecht, The Netherlands). Computer searches
were carried out using the UWGCG program (Devereux, 1992).
RNase protection assay
A PstI fragment containing bp 1243-1640 from C14 was subcloned
in pBluescript KS (Stratagene) and used to generate [32P]UTP-
labelled anti-sense transcripts in vitro. The follicle-stimulating
hormone receptor (FSHR) RNA probe was obtained using a 386 bp
HindIII/PvuII fragment from the rat cDNA (Sprengel et al., 1990).
The activin receptor type II (ActRII) RNA probe was obtained using
a 569 bp rat ActRII cDNA fragment (de Winter et al., 1992). The
control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) RNA
probe was synthesized using a construct containing a 291 bp
XbaI/Sau3AI fragment from rat GAPDH cDNA (Fort et al., 1985).
Approximately 5· 104 cts/minute of C14, FSHR, or ActRII probe,
together with 5· 104 cts/minute of GAPDH probe, was mixed with 5
or 10 m g of total RNA in a total volume of 30 m l hybridization mixture
containing 40 mM Pipes pH 6.4, 1 mM EDTA, 0.4 M NaCl and 80%
(v/v) formamide. The hybridizations were performed overnight at
55˚C. The RNase protection assay was performed as described by
Sambrook et al. (1989).
In situ hybridization
The C14 subclone that was used for RNase protection assays was also
used to prepare sense and anti-sense 35S-UTP-labelled transcripts in
vitro. The probes were dissolved in 5 m l 0.2 M DTT. Immediately
prior to use, the probe solution was mixed with 5 m l of 30 m g/m l S-
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ATP (Calbiochem, Omnilabo, Breda, The Netherlands), incubated at
100˚C for 1 minute and diluted in prewarmed (55˚C) hybridization
mixture to a final concentration of approximately 2· 105 cts /minute
per m l. The hybridization mixture contained: 50% (v/v) deionised
formamide, 0.3 M NaCl, 10 mM Tris pH 8, 1 mM EDTA, 1·
Denhardt’s solution, 1 mg/ml yeast tRNA, 50 mM DTT and 10%
(w/v) polyethylene glycol 6000.
The lower body region of embryos at E15 and E16 was separated
from the head region and fixed in fresh Bouin’s fixative overnight at
4˚C. All in situ hybridization procedures (tissue embedding, slide
preparations, pretreatments, hybridization and posthybridization incu-
bations) were performed as described by Zeller and Rogers (1991).
The tissue was embedded in paraffin, and 8 m M sections were
mounted on slides which were coated with poly-L-lysine. Adjacent
sections where mounted and stained with Mayer’s haematoxylin and
eosin for tissue and cell identification. The hybridizations were
performed at 55˚C overnight in moist chambers. The slides were
dipped in 1:1 (v/v) dilution of Kodak NTB-2 emulsion and dried at
room temperature for 2 hours, followed by exposure at 4˚C for 2
weeks. After developing, the sections were counterstained with
Nuclear fast red and mounted.
Genomic DNA isolation and PCR procedures
The head region of the embryos at E15 and E16 was snap frozen in
liquid nitrogen and used for genomic DNA isolation according to
Davis et al. (1986). This DNA was used in a DNA amplification
reaction (Saiki et al., 1988) using primers for mouse Sbx and Sby
(Mitchell et al., 1991, Kay et al., 1991) as described by Mitchell et
al. (1991). The product obtained with the
Sbx primers (approximately 250 bp) was
used as a positive control to test the
quality of the DNA, and the presence or
absence of a product with the Sby primers
(approximately 1000 bp) was used to
determine the sex of the embryos (results
not shown).
RESULTS
Selection of C14
C14 was isolated from a Sertoli cell
cDNA library as described in
Materials and methods. The 1.9 kb
C14 cDNA probe hybridizes on
northern blots to a major transcript of
approximately 2.5 kb, which is
expressed at high levels in cultured
Sertoli cells (Fig. 1). However, there
was no significant stimulation of the
expression by testosterone. The tissue
specificity of C14 mRNA expression
was determined using an RNase pro-
tection assay. Fig. 2 shows that C14
mRNA expression in the adult rat is
mainly restricted to the gonads.
Based upon this marked tissue speci-
ficity of C14 mRNA expression, C14
was selected for further investigation.
C14 sequence analysis
The complete 1.9 kb C14 cDNA was
sequenced. It contains a single open
reading frame that encodes a 557
amino acid protein, starting from the first methionine codon at
residue 60 (Fig. 3A). This ATG codon and its context form a
potential functional initiation site (Kozak, 1987). Analysis of
the protein sequence indicated the presence of a signal
sequence with a predicted cleavage site before Gln16 (von
Heijne, 1986). A hydrophobic region between amino acid
residues 142-168 represents the single putative transmembrane
domain (TMD). Thus, the mature protein consists of an extra-
cellular domain of 126 amino acid residues, a TMD of 27
amino acid residues, and an intracellular domain of 389 amino
acid residues. The extracellular domain is cysteine rich and
contains 2 potential N-glycosylation sites. 
EMBL and GenBank database searches revealed that the
intracellular domain of C14 is most closely related to the intra-
cellular domains of the mouse activin receptor types II (ActRII;
Mathews and Vale, 1991) and IIB (ActRIIB; Attisano et al.,
1992), the human TGF-b type II receptor (TGF-b RII; Lin et
al., 1992), the mouse TGF-b type I receptor (TGF-b RI; Ebner
et al., 1993), and the C. elegans orphan receptor Daf-1 (Georgi
et al., 1990) (Fig. 3B). The ActRII, ActRIIB, TGF-b RII, TGF-
b RI and Daf-1 together form a separate subfamily of receptors
with intrinsic protein kinase activity (Mathews and Vale, 1991;
Lin et al., 1992). Recently, several rat orphan receptors have
been cloned, that are also members of this newly defined
receptor family (He et al., 1993). 
The C14 intracellular kinase domain contains the 12 subdo-
mains, which are found in all protein kinases, in the proper
order (Hanks et al., 1988), and also contains the two inserts
located between subdomains VI-A and VI-B and between sub-
domains X and XI, that are characteristic for the subfamily
(Mathews and Vale, 1991). The percentage identical amino
acids of the kinase domain of C14 compared to the ActRII,
TGF- b RII, TGF-b RI and Daf-1 kinase domains is 34%, 32%,
33% and 29%, respectively. 
The sequences in the kinase subdomains VI-B and VIII
indicate substrate specificity (Hanks et al., 1988). The relevant
sequences in C14 within these subdomains are more in accor-
dance with the serine/threonine kinase consensus sequence
than with the tyrosine kinase consensus sequence, with the
exception of serine residue 333. At this position in the kinase
domain, a lysine residue is found in almost all known
serine/threonine kinases including ActRII, ActRIIB, TGF-
b RII, TGF-b RI and Daf-1. 
The extracellular domains of C14, ActRII and TGF-b RII
show a relatively low level of sequence identity (Fig. 3C).
However, the position of most cysteine residues is conserved.
Fig. 1. C14 mRNA
expression in cultured
Sertoli cells. C14
cDNA probe was
hybridized to a
northern blot
containing 20 m g total
RNA isolated from
Sertoli cells cultured
in the absence (- ) or
presence (+) of
testosterone (see also
Materials and
methods). Clone 14
indicates the 2.5 kb
band of C14 mRNA,
abundantly expressed
under both culture
conditions. The
GAPDH hybridization
indicates that equal
amounts of mRNA
were loaded in each
lane. 18S and 28S
indicate the locations
of the respective
rRNA bands.
Fig. 2. Tissue specificity of C14 mRNA expression. RNase
protection assays were used to study the expression of C14 mRNA in
different tissues. From 4-week-old rats: Te, testis; Oa, ovary; Ut,
uterus. From adult rats: Oi, oviduct; Pr, prostate; Ep, epididymis; Se,
seminal vesicle; Br, brain; Pi, pituitary gland; He, heart; Lu, lung;
Sp, spleen; Li, liver; Ki, kidney; In, intestine; Mu, muscle. 10 m g of
total RNA was used for each lane. C14 indicates the position of the
protected RNA fragment. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) mRNA was present in all samples (not
shown).
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C14 expression during embryonic sexual
differentiation
The fact that C14 encodes a member of the activin and TGF-
b type I/II receptor family, indicates that the C14 ligand will
be a member of the activin and TGF-b -family of peptide
growth factors. C14 is expressed mainly in the gonads in adult
rats (present results), where anti-müllerian hormone (AMH)
may perform specific functions (Hirobe et al., 1992; Münster-
berg and Lovell-Badge, 1991). This pointed to AMH as an
important candidate ligand for C14. To investigate this possi-
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Fig. 3. Analysis of C14 cDNA. (A) The
complete 1920 bp cDNA clone
sequence encoding a protein of 557
amino acid residues is shown. The
kinase domain is in bold type. The
hydrophobic signal sequence and
transmembrane region are underlined,
and the potential N-glycosylation sites
are double underlined. (B) Comparison
of the kinase domain of rat C14 to the
kinase domains of mouse ActRII and
human TGF-b RII. The Roman numerals
under the sequence indicate the kinase
subdomains. The inserts between
subdomains VI-A and VI-B and
between subdomains X and XI are
underlined. The asterisk denotes the
location of serine residue 333. 
(C) Comparison of the extracellular
domain of C14 to the extracellular
domains of ActRII and TGF-b RII. In B
and C reversed script is used to
highlight amino acid residues that are
found in at least two of the three kinase
receptors. 
A
B
C
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Fig. 4. Expression of C14 mRNA at E15 and E16. Bright-field photomicrographs from in situ hybridization of the antisense C14 RNA probe to
paraffin sections (A,C,E,G) and from haematoxylin/eosin stained adjacent sections (B,D,F,H) of female embryos at E15 (A,B), E16 (C,D), and
of male embryos at E15 (E,F) and E16 (G,H). Embryonal sex was determined as described in Materials and methods. g, gonad; arrowhead,
wolffian duct; arrow, müllerian duct. Hybridization of the sense control C14 RNA probe did not result in signals above background (not
shown).
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bility, the expression pattern of C14 mRNA in the urogenital
ridge of rat embryos during the induction of müllerian duct
regression was studied.
Using in situ hybridization, marked C14 mRNA expression
was detected in the female gonads, but not in the male gonads,
of embryos at E15 and E16 (Fig. 4A-H). Furthermore, C14
mRNA is expressed in the female urogenital ridges at E15 and
E16, in a sickle-shaped area that includes the mesenchymal
cells between the müllerian duct and the coelomic epithelium
(Fig. 4A-D). In the male urogenital ridges at E15, the
expression of C14 mRNA is identical to the E15-E16 female
pattern (Fig. 4E,F). However, this male expression pattern has
clearly changed at E16, when C14 mRNA is present in a small
circular area that includes the degenerating müllerian duct (Fig.
4G,H). No other sites of C14 mRNA expression above back-
ground were detected in the lower body halves of the embryos
at E15 and E16.
RNase protection assays were used to study the expression
of C14 mRNA in isolated urogenital ridges and gonads at E15,
E16 and E19 (Fig. 5). C14 mRNA was detected at much higher
levels in ovary than in testis at all embryonic stages tested. At
E15, C14 mRNA expression in the urogenital ridge was
detected at approximately equal levels in both male and female
embryos. However, at E16, the C14 mRNA level in the male
urogenital ridge is lower than in the female urogenital ridge.
Finally, at E19, C14 mRNA was not detected in the male uro-
genital ridge, whereas the C14 mRNA level remains high in the
female urogenital ridge. No C14 mRNA was detected in total
RNA isolated from E19 intestine, skin, lung, liver, kidney,
adrenal, stomach, heart, thymus, muscle, and brain (not shown).
Postnatal expression of C14 mRNA in testis and
ovary
Different testicular cell types were isolated, to study the
cellular location of C14 mRNA expression in the testis using
RNase protection assay. It was observed that C14 mRNA is
specifically expressed in Sertoli cells, at equal levels in cells
isolated from 21-day-old or mature rats (Fig. 6A). No C14
mRNA was detected in round spermatids and peritubular
myoid cells. ActRII mRNA, which is expressed at a high level
in round spermatids (de Winter et al., 1992), was used to verify
the integrity of the round spermatid mRNA. FSHR mRNA,
which is expressed exclusively in Sertoli cells (Heckert and
Griswold, 1991), was used to show the cellular colocalization
of FSHR and C14 mRNAs and the absence of Sertoli cell con-
tamination from the other isolated cell types. 
C14 mRNA expression in total testis is very low at birth,
and increases to a maximum at day 21 of postnatal develop-
ment (Fig. 6B). Since we found similar levels of expression in
Sertoli cells from immature and adult rats (Fig. 6A), the
relative decrease in C14 mRNA expression in total testis
between days 21 and 63 can be explained by the increasing
population of C14-negative spermatids. 
In the ovary of adult rats, marked expression of C14 mRNA
was detected, using in situ hybridization, in the granulosa cell
layers of small antral follicles (not shown).
DISCUSSION
Based upon the observation that in adult rats C14 mRNA
expression is most abundant in the gonads, C14 was selected
and characterized. C14 encodes a novel member of the activin
and TGF- b type I/II serine/threonine kinase receptor family.
Including C14, nine members of this gene family are presently
known: Daf-1 encoding an orphan receptor (Georgi et al.,
1990), TGF-b RII (Lin et al., 1992), TGF-b RI (Ebner et al.,
1993), R2, R3 and R4, which are three orphan receptors cloned
through PCR amplification of rat fetal urogenital ridge cDNA
with a relatively high percentage of similarity to TGF-b RI in
the kinase domain (He et al., 1993), and two genes encoding
the different activin type II receptors, ActRII and ActRIIB
(Mathews and Vale, 1991; Attisano et al., 1992). The sequence
identity between ActRII and ActRIIB is 51% in the extracel-
lular domain and 75% in the intracellular domain, and four
different splice variants of ActRIIB have been described
(Attisano et al., 1992).
There is complete structural homology between C14 and the
other members of the serine/threonine kinase receptor family.
The C14 kinase domain has the highest degree of amino acid
identity with the kinase domain of ActRII (34%). However, the
ActRII and TGF-b RII kinase domains are more closely related,
showing 45% amino acid identity to one another. It has been
shown by Nakamura et al. (1992) that ActRIIB is a dual speci-
ficity kinase, which can phosphorylate serine/threonine as well
as tyrosine residues. It remains to be determined whether the
change from the conserved lysine to a serine at position 333 in
the C14 kinase domain has
any significance with
respect to substrate speci-
ficity or kinase activity.
Our hypothesis that
AMH could be an
important candidate ligand
of C14 implies that C14
mRNA should be
expressed in the urogenital
ridge during the induction
of müllerian duct degener-
ation by AMH, around day
15 of embryonic develop-
ment in the rat (Jost, 1947;
Tsuji et al., 1992). It was
observed that C14 mRNA
is expressed in an area that
includes the mesenchymal
cells between the
müllerian duct and the
coelomic epithelium at
E15, in both male and
female embryos. Recent
results have shown that
AMH can reduce DNA
synthesis of cultured uro-
genital ridge mesenchymal
cells but not of cultured
müllerian duct epithelial
cells (Tsuji et al., 1992).
This suggests that AMH
most likely elicits its effect
upon the müllerian duct
epithelium via the sur-
rounding mesenchyme
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Fig. 5. Expression of C14 mRNA in
different embryonal tissues at E15,
E16 and E19. Embryos were
collected at E15 (A); E16 (B) and
E19 (C), and C14 mRNA
expression was studied using RNase
protection assays in: Lane 1, ovary;
2, female urogenital ridge; 3, testis;
4, male urogenital ridge. C14 and
GAPDH indicate the positions of
the respective protected fragments. 
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(Tsuji et al., 1992). Light and electron microscopic studies
have demonstrated that the regression of the müllerian duct
epithelium is closely associated with changes in the surround-
ing mesenchymal cells and changes in the epithelial-mes-
enchymal interface. One of the observed changes during
müllerian duct regression is the formation of a dense circular
whorl of mesenchymal cells around the epithelial duct
(Trelstad et al., 1982). These observations on the cellular sites
of AMH action and histological changes associated with
müllerian duct regression, correlate with C14 mRNA
expression. 
The level of C14 mRNA in the urogenital ridges at E16 is
relatively low in male compared to female embryos. At E19,
C14 mRNA is expressed at a high level in the female urogen-
ital ridge whereas at this stage it is no longer detected in the
male urogenital ridge. This correlates with the gradual degen-
eration of the müllerian ducts in male embryos between E16
and E19 (Trelstad et al., 1982). Furthermore, in the female, the
AMH receptor indeed persists after the critical period of
induction of müllerian duct regression as can be concluded
from the observation that AMH induces the formation of
bulges in the cranial portion of the müllerian duct, in cultured
urogenital ridges that were isolated from female embryos at
E18.5 (Tsuji et al., 1992). 
Using in situ hybridization at E15 and E16, marked C14
mRNA expression was detected in developing ovaries but not
in testes. However, using RNase protection assays at E15, E16
and E19, C14 mRNA was detected at low levels in the testis
(and at a high level in the ovary); the RNase protection assay
appears to be more sensitive than in situ hybridization. In view
of this C14 mRNA expression in fetal testis, AMH and its
receptor might be involved in normal testis differentiation in
the male. Overexpression of AMH in transgenic mice can
induce formation of testis cord-like structures in fetal ovaries
(Behringer et al., 1990). Furthermore, AMH exerts an
inhibitory effect on aromatase activity in cultured fetal ovaries
(Vigier et al., 1989). Aromatase catalyzes the conversion of
testosterone to estradiol during female gonadal development,
and inhibition of ovarian aromatase activity by AMH leads to
production of testosterone rather than estradiol. These biolog-
ical responses to AMH suggest that the AMH receptor indeed
is present in fetal ovaries, where it is probably inactive due to
the absence of AMH. Following day 3 of postnatal develop-
ment, AMH is expressed in the ovary where it might play a
role in oocyte maturation (Hirobe et al., 1992; Münsterberg and
Lovell-Badge, 1991). In agreement with this, we observed
postnatal ovarian expression of C14 mRNA in the granulosa
cells of small antral follicles. Future studies will have to
provide more information about the pattern and regulation of
C14 mRNA expression in the ovary.
It is not known whether AMH plays a physiological role in
the testis after birth. We have shown that C14 mRNA
expression increases in Sertoli cells to a maximum during
postnatal testis development, and remains high in the adult rat
testis. With respect to testicular production of the ligand, it is
known that testicular AMH mRNA expression decreases after
birth, but persists at a low level throughout adulthood (Lee et
al., 1992). Low levels of AMH may exert autocrine actions
upon Sertoli cells in immature and mature testis. It is also
possible that testicular AMH production varies at different
stages of the spermatogenic cycle and hence involves local
concentration gradients. Inherited defects in the biosynthesis
of AMH do not seem to have a major effect on male fertility
(Josso, 1992), but this does not exclude a quantitative defect
in spermatogenesis. Moreover, other testicular factors
(possibly members of the activin and TGF-b family of peptide
growth factors) may partly compensate for a lack of AMH by
binding to their specific receptors and activation of similar
intracellular pathways.
The present results are in accordance with - but do not
provide conclusive evidence for - the hypothesis that C14
encodes an AMH receptor. Evidence might be provided by
showing AMH binding to cells that are transfected with a C14
expression vector. However, attempts that have been made in
the past to show binding of AMH to its receptor on AMH-
responsive cells have been hampered by the fact that radiola-
belling of AMH seems to abolish its ability to bind to the
receptor (Donahoe et al., 1977). Furthermore, conclusive
results that identify a receptor ligand through a binding assay
using a cell line that stably expresses the relevant receptor,
might be difficult to obtain if this receptor behaves as a type I
receptor; such a receptor would require cooperation with a
specific type II receptor which may not be endogenously
expressed in the cell line used. To resolve these problems, it
will be necessary to develop a binding assay for AMH. Then
the possible existence of different types of AMH receptors can
be studied, and suitable model cell lines can be developed to
test candidate receptors for ligand binding.
The persistent müllerian duct syndrome (PMDS) is a rare
form of male pseudohermaphroditism that is characterized by
Fig. 6. C14 mRNA expression in testis. (A) The expression of C14,
activin type II receptor (ActRII) and follicle-stimulating hormone
receptor (FSHR) mRNAs in different testicular cell types,
determined using RNase protection assays: Lane 1, 21-day-old rat
Sertoli cells; 2, adult rat Sertoli
cells; 3, round spermatids
isolated from 35-day-old rat
testis; 4, peritubular myoid cells
(PMC) isolated from 21-day-
old rat testis. C14, ActRII and
FSHR indicate the positions of
the respective protected
fragments. (B) C14 mRNA
levels in total testis from rats of
different ages using RNase
protection assays. The numbers
above each lane correspond to
the postnatal age in days of the
rats. C14 and GAPDH indicate
the positions of the respective
protected fragments. GAPDH
mRNA levels are included in
this figure to show that the
mRNA was intact.
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the presence of uterus and fallopian tubes in otherwise
normally virilized males (Josso et al., 1991). In some of these
patients it has been shown that the phenotype is caused by a
mutation in the AMH gene (Knebelmann et al., 1991), but
other patients express a normal amount of bioactive testicular
AMH (Guerrier et al., 1989). The existence of this type of
PMDS indicates that mutation of the AMH receptor gene(s)
can result in a complete loss of responsiveness to AMH. In the
future, ultimate proof that C14 encodes an AMH receptor can
be obtained through genetic analysis of PMDS, or when knock-
out transgenic mice are generated that show the characteristics
of PMDS.
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